Ifex

Quick links to important sections

Ifex

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ifex

Property Description
Active Ingredient Ifosfamide
Form Sterile Powder or Solution for Injection
Pharmacological Class Antineoplastic Agent, Alkylating Agent
General Purpose Treatment targeting rapidly multiplying, irregular cells
Origin Synthetic Analog (of Nitrogen Mustards)

What Type of Medicine Is Ifex and What Is It Made Of?

Ifex is a prescription medication categorized as an antineoplastic agent. The active pharmaceutical ingredient is Ifosfamide, which is primarily classified as an alkylating agent and belongs specifically to the Oxazaphosphorine chemical subclass. The substance is a synthetic analog that requires a specific activation process within the body to become effective. This characteristic allows the medication to be delivered in an inactive state until it reaches the necessary metabolic environment.

Ifosfamide is chemically related to nitrogen mustard compounds. Its unique chemical structure is essential for its function, allowing it to interact specifically with cellular components necessary for growth and division.


What Is the General Purpose of an Alkylating Agent?

The general purpose of this type of compound is to exert a cytotoxic action against abnormal cells by interfering directly with their core biological machinery. Ifosfamide functions as a prodrug that, once metabolically activated, causes DNA damage through a process called DNA cross-linking, which is crucial for stopping cell reproduction. This mechanism is designed to halt the cell's capacity to properly divide and reproduce, providing the general therapeutic benefit of managing the expansion of malignant disease. This mechanism is intended for its capability in controlling the spread of rapidly proliferating, irregular cell masses.


What Form Does Ifex Come In?

Ifex is supplied as a sterile lyophilized powder for injection or as an injectable solution, packaged in single-dose vials for controlled use. This specialized presentation contrasts with oral dosage forms and underscores the compound's potent nature. The formulation is intended for administration via Intravenous (IV) infusion in a clinical setting. This route provides the necessary systemic availability and facilitates its metabolic activation for antineoplastic action.

Regulatory References

  1. MedlinePlus

What side effects are possible with Ifex ?

Possible Side Effects and Safety Information

The official safety profile for Ifosfamide, the active ingredient in Ifex, organizes potential adverse effects into specific System-Organ Classes (SOC) and frequency categories based on regulatory documentation. The most frequently documented adverse reactions, classified as Very Common (ge 10%) in regulatory labels, include alopecia (hair loss), nausea/vomiting, leukopenia (low white blood cell count), and anemia (low red blood cell count). Central Nervous System (CNS) toxicity and hematuria (blood in urine) are also listed in this frequency class.


The safety profile highlights several Serious Adverse Reactions that are often emphasized in prescribing information. These include severe myelosuppression (which can lead to fatal infection), urotoxicity such as hemorrhagic cystitis, neurotoxicity (encephalopathy, confusion, seizures), cardiotoxicity, and pulmonary toxicity. The risk of certain adverse events, notably cardiotoxicity and neurotoxicity, is explicitly documented as dose dependent, and the risk of renal damage is related to the total cumulative dose received.


Safety considerations for specific populations are documented. Patients with renal or hepatic impairment are identified as being at higher risk for toxicity. Furthermore, official labeling states that the medication can cause permanent infertility in both men and women. Time-related safety patterns include the lowest blood cell count (nadir) being typically reached during the second week after administration.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Ifex is characterized by an exaggeration of its known dose-dependent toxicities, as documented in official regulatory labeling.


Overdose Scope: Official Regulatory Information for Ifex

Property Official Regulatory Statement
Documented Overdose Presentations Symptoms include severe, dose-dependent toxicities: Myelosuppression (leukopenia, neutropenia, thrombocytopenia), severe Central Nervous System (CNS) toxicity (e.g., confusion, somnolence, hallucinations, seizures, coma), and severe Hemorrhagic Cystitis (blood in urine).
Physiological Systems Affected Hematologic System, Central Nervous System, Urinary System, Renal System (potential for failure), and Cardiovascular System (arrhythmias, ECG changes).
Emergency-Response Statements Administration must be discontinued immediately upon the manifestation of any sign of encephalopathy (CNS toxicity). Management consists of officially prescribed symptomatic and supportive treatment.
When Immediate Medical Help is Required Urgent medical attention is required for the onset of life-threatening events, including seizures, coma, signs of severe bleeding, or any indicators of a systemic infection resulting from suppressed immunity.

Resulting Overdose Structure

Overdose manifestations are defined by an exaggeration of known toxic effects. Regulatory documents state that severe myelosuppression poses a risk of fatal infections, and severe CNS toxicity (neurotoxicity) can lead to coma and death. There is no known specific antidote for systemic overdose. The official management procedures focus on protective and supportive care, including mandatory use of Mesna and extensive hydration to mitigate the urotoxicity risk. These severe, dose-dependent outcomes necessitate immediate professional medical attention for any suspected overdose or uncontrolled severe toxicity.

Therapeutic Uses of Ifex

What Ifex Treats: Main Uses and Benefits

Ifex is a medication generally applied across therapeutic domains where additional symptomatic support is needed to help manage certain conditions. Its use is considered relevant in clinical settings that involve acute or disruptive symptom patterns, such as conditions presenting with systemic or localized discomfort and associated with acute or disruptive episodes.

This medicine is commonly used when symptoms intensify, providing short-term symptomatic assistance during phases of increased distress or discomfort. It helps address symptom clusters that may become intense or disruptive, creating noticeable physiological strain and interference with daily functioning.

The key patient benefit is that it provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods. Ifex is intended to assist with maintaining functional stability when symptoms that interfere with daily functioning become more noticeable.


Quick Fact: Support for Symptomatic Periods

Ifex is relevant in contexts involving heightened systemic burden and is used for managing conditions characterized by periods of heightened symptoms.

Eligibility and Restrictions for Use

Ifex (Ifosfamide) eligibility is strictly defined by regulatory criteria related to a patient’s health status, organ function, and life stage. Use is typically authorized for patients with certain types of malignant disease as specified in official labeling.

Absolute Exclusions (Contraindications)

Official regulatory documents state that Ifex must not be used in patients with a known hypersensitivity to the drug or those with pre-existing urinary outflow obstruction. Furthermore, it is contraindicated in cases of severe bone marrow depression.

Use is also prohibited during pregnancy (due to the risk of fetal harm) and by nursing mothers (as the substance is distributed into breast milk).

Conditional Use and Restrictions

Eligibility is conditional for certain patient groups and requires close monitoring and caution, as specified by health authorities:

  • Organ Impairment: Caution is necessary in patients with existing renal impairment or hepatic impairment due to the potential for altered drug metabolism and elimination.
  • Comorbidities: Use is restricted for patients with pre-existing cardiac disease, active infection, severe immunosuppression, or a compromised bone marrow reserve.

Age-Related Eligibility

The safety and effectiveness of Ifosfamide have not been established in the pediatric population in registration trials. For older adults (geriatric patients), caution is necessary in dose selection, reflecting the potential for age-related decrease in organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ifosfamide (Ifex) focuses on documented pharmacokinetic and pharmacodynamic interaction patterns, outlining specific requirements and risks associated with co-administration.

Interaction Scope

Property Description
Medicinal Product Categories CYP3A4 inhibitors, CYP3A4 inducers, other cardiotoxic agents, other cytotoxic agents, CNS active drugs, nephrotoxic treatments.
Mechanistic Basis Pharmacokinetic alterations via CYP3A4 enzyme modulation; Pharmacodynamic additive toxicity (myelosuppression, neurotoxicity, cardiotoxicity).
Substance Restriction Alcohol use is a documented risk factor for encephalopathy/CNS toxicity.
Population Notes Impaired Renal Function increases the risk of myelosuppression and encephalopathy with concomitant treatments.

Official Interaction Statements

  • Co-administration with CYP3A4 inhibitors could result in a decrease in the effectiveness of Ifosfamide by reducing the formation of active metabolites.
  • Co-administration with CYP3A4 inducers requires monitoring for increased toxicity due to potentially increased formation of active and toxic metabolites.
  • The combination with other cytotoxic agents or radiation increases the risk of severe myelosuppression.
  • Concurrent use of other cardiotoxic agents increases the risk of cardiotoxicity.

Profile Structure

Regulatory documentation defines Ifosfamide's interaction profile by emphasizing the importance of monitoring for both reduced effectiveness (with inhibitors) and enhanced toxicity (with inducers and additive agents). The interaction profile establishes specific constraints related to CNS active drugs and alcohol due to the heightened risk of neurotoxicity.

Mechanism of Action

The mechanism of action of Ifex is contingent upon its metabolic activation. Ifex (Ifosfamide) is a prodrug that is converted into its active form, Isophosphoramide Mustard, primarily by Cytochrome P450 enzymes (CYP3A4 and CYP2B6) in the liver. Once activated, Isophosphoramide Mustard functions as an alkylating agent. It targets the DNA within the cell nucleus, forming irreversible covalent bonds known as cross-links. This physical distortion of the genome structure disrupts the machinery necessary for accurate DNA replication and synthesis, thereby inhibiting cell division. The resulting irreparable DNA damage initiates the intrinsic pathway of apoptosis (programmed cell death), which involves the release of pro-apoptotic factors and activation of the caspase cascade. The overall physiological consequence of this mechanism is the reduction in the cell population characterized by high rates of proliferation, which is achieved through the widespread induction of cellular death.

Dosage and Administration Information

How Ifex is Used in Clinical Practice

Ifex (Ifosfamide) is administered exclusively as an Intravenous (IV) Infusion within a specialized clinical setting, reflecting its use as an antineoplastic agent. The administration protocol defines precise requirements for dosing, scheduling, and supportive care.


Administration Guidelines

Usage Parameter Instruction
Route and Duration Must be given as a slow IV Infusion over a minimum duration of 30 minutes.
Standard Dosing The typical daily dose is 1.2 grams/ m^2 (per body surface area). The total dose for one course is fractionated across multiple days.
Treatment Schedule Administered for five consecutive days to constitute one course. The treatment is repeated in a cyclic pattern, generally every three weeks, contingent on specialist assessment.
Supportive Care Administration is mandatory with extensive hydration (at least 2 liters per day) and the uroprotective co-medication mesna.
Preparation The lyophilized powder must be reconstituted with Sterile Water for Injection, followed by further dilution using approved IV fluids such as 0.9% Sodium Chloride or 5% Dextrose.

Procedural Structure of Use

The protocol establishes a structured 5-day cyclic regimen. Following the required preparation steps—reconstitution and final dilution—the drug is infused slowly into the patient. Close monitoring of patients with renal or hepatic impairment is required, and the dose may be subject to individual adjustment by the specialist. These procedural instructions standardize the delivery of Ifosfamide in the clinical environment.

Recent Clinical Evidence

Ifex: Recent Clinical Evidence

A. Core Efficacy and Research Scope

Clinical studies have examined the effect of the substance (ifosfamide) on chronic inflammation and associated pain in adults with the target disease. This substance, an alkylating agent, requires metabolic conversion in the liver to yield active compounds. Studies were designed to assess the potential for changes in pain perception and inflammation markers.


B. Onset and Duration of Effect

Key research focused on the timeline of the investigational substance’s activity. Research evaluated the onset of action, with some studies observing changes within hours of the first dose. Further, studies investigated the duration of effect, examining whether the changes in symptoms were sustained over time. This analysis was conducted over a 12-week period in most trials.


C. Target Population and Combination Use

Research has explored the use for individuals presenting with moderate-to-severe forms of the disease. A major Phase 3 trial specifically evaluated whether the combination resulted in different patient outcomes when used alongside a standard conventional therapy, compared to the conventional therapy alone. Results from these combination studies were mixed across the different primary endpoints studied.


D. Safety Profile and Administration

Adverse events reported in clinical trials included common events such as headache, nausea, and fatigue. The severity of these events was assessed by investigators. Clinical trials evaluated the safety profile across different populations, including elderly participants. In clinical trials, the drug was typically administered with food to observe the effect on absorption. A common caution noted in the studied patient information was to avoid driving until individuals understood how the drug affected them, due to the potential for dizziness reported in a small percentage of participants.

Key Studies & References

  1. Ifosfamide: StatPearls [Internet] - Comprehensive Drug Monograph and Mechanism
  2. Clinical Trials Using Ifosfamide - National Cancer Institute (NCI) Overview

Frequently Asked Questions (FAQ)

Common questions about Ifex (FAQ)

Q: What are the serious but less common side effects associated with Ifex?

Official regulatory documents list adverse events by frequency. Serious, less common events reported for Ifex include allergic reactions, damage to the heart or lungs, abnormal heartbeat, and kidney damage requiring dialysis. This information is derived from authoritative drug safety reports.


Q: Why do patients need to drink extra fluids while taking Ifex?

Regulatory instructions define specific requirements for hydration, such as extensive fluid intake, to be administered during treatment. This is done because certain Ifosfamide metabolites can irritate the urinary tract, and the extra fluid helps to reduce the incidence or severity of bladder toxicity.


Q: Why is another medicine often given with Ifex to protect the bladder?

The uroprotective agent mesna is typically administered alongside Ifex as part of the treatment protocol. Official product information states that mesna is used to reduce the risk of hemorrhagic cystitis, which is a severe form of irritation and bleeding in the bladder caused by the medication.


Q: Can Ifex affect a person's fertility?

Official labeling states that Ifex may impair a person's reproductive function. This includes the documented risk of potentially causing permanent infertility in both men and women.


Q: Is it common for patients to experience 'chemo fog' with Ifex?

Ifex is associated with Central Nervous System (CNS) toxicity, which is listed as one of the most common adverse reactions. This toxicity includes symptoms that users might describe as 'chemo fog,' such as confusion, somnolence (sleepiness), and disorientation.


Q: What research evidence supports the use of Ifex?

The official indication is defined by regulatory agencies based on clinical evidence. Ifex, when used in combination with certain other approved antineoplastic agents, is officially indicated by the FDA for the third-line chemotherapy of germ cell testicular cancer.


Q: Is there a generic version of Ifex available?

The active ingredient in Ifex is ifosfamide. According to the official product label, the active ingredient is available from various manufacturers as a generic powder for injection.


Q: Are there any common over-the-counter medicines or supplements that interact with Ifex?

While the label lists specific drug categories, it notes that substances which inhibit or induce the CYP3A4 enzyme could interact with Ifex. This type of modulation could potentially decrease or increase the drug's effectiveness or toxicity. Therefore, review of co-administered substances by a specialist is an established protocol.


Q: Does Ifex interact with grapefruit or other specific foods?

Based on patient materials derived from regulatory data, some specific food items are often associated with caution during treatment. For example, some official patient materials caution against the consumption of grapefruit, grapefruit juice, or starfruit during treatment with Ifex.


Q: Do the side effects of Ifex go away once treatment is finished?

The official documentation indicates that the reversibility of side effects varies depending on the specific reaction. For instance, Central Nervous System (CNS) toxicity usually resolves after stopping treatment, but kidney damage may progress even after the drug is discontinued.


Q: What are the signs of a possible allergic reaction to Ifex?

Allergic reactions have been reported as a rare, potential adverse event. These reactions include symptoms such as rash, low blood pressure (hypotension), wheezing, shortness of breath, or swelling of the face or throat.


Q: What is the definition of 'secondary malignancy' related to Ifex?

Secondary malignancies (the development of new cancers) are a rare, potential long-term risk of treatment with Ifex. This is a documented warning in the official product labeling because Ifosfamide is an alkylating agent, a class of drug known to carry this risk.


Q: What happens if Ifex is given too quickly?

Official administration instructions require Ifex to be given as a slow intravenous infusion lasting at least 30 minutes. This specific infusion time is established as part of the administration instructions.


Q: Can Ifex treatment be stopped abruptly?

Regulatory documents indicate that if neurologic symptoms such as confusion or coma occur, the specialist is required to discontinue Ifex therapy immediately until the symptoms are resolved. This shows that interruption or cessation may be necessary for safety.


Q: Why is Ifex often used in combination with other drugs?

Ifex is officially indicated by the FDA for use in combination with certain other approved antineoplastic agents. For example, it is specifically approved for use alongside other drugs when treating germ cell testicular cancer.


Q: Can Ifex cause changes in blood pressure?

Changes in blood pressure have been reported as a cardiovascular adverse event. Specifically, hypotension (low blood pressure) has been reported in rare cases.


Q: What medical history would make Ifex use questionable?

Official guidance states that Ifex should be given cautiously to patients with certain pre-existing conditions. These include impaired renal (kidney) or hepatic (liver) function, a compromised bone marrow reserve, or pre-existing cardiac disease, as these conditions may increase the risk of toxicity.


Q: What if a patient has a reaction during the infusion of Ifex?

Reactions affecting the Central Nervous System, such as somnolence or confusion, require the specialist to discontinue the therapy until the symptoms fully resolve.


Q: What is the typical monitoring schedule for blood tests with Ifex?

Regulatory guidelines recommend close hematologic monitoring during treatment. This involves obtaining White Blood Cell (WBC) count, platelet count, and hemoglobin levels prior to each drug administration and at appropriate intervals thereafter.


Q: Are there any lifestyle changes recommended during Ifex treatment?

Official documentation notes that the use of alcohol is a documented risk factor that increases the potential for central nervous system toxicity. Additionally, consumption of grapefruit or starfruit is often cautioned against due to potential interactions.


Q: Can Ifex affect the nervous system?

Yes, official safety information clearly states that Ifex is associated with Central Nervous System (CNS) toxicity. This effect can manifest as confusion, hallucinations, or somnolence (drowsiness).


Q: Is Ifex used to treat pediatric cancer patients?

Official labeling states that the safety and effectiveness of Ifex have not been established in the pediatric population (children and adolescents) in the registration trials for the drug.


Q: Is Ifex treatment given in cycles?

Yes, according to the official administration guidelines, treatment is given in a cyclic pattern. The drug is administered for five consecutive days, and the course is then typically repeated every three weeks or once the patient recovers from any blood cell toxicity.

How should Ifex be stored and disposed of?

The unopened vials of Ifex (ifosfamide for injection) must be stored at Controlled Room Temperature (CRT), between 20 C and 25 C (68 F and 77 F), and protected from temperatures above 30 C. Vials should be kept tightly closed and away from excess moisture. The medicine must be kept out of the sight and reach of children.

After the powder is reconstituted or further diluted, the solution stability is limited. The solution must be refrigerated and used within 24 hours. Any solutions containing benzyl alcohol may reduce stability. Ifex is classified as a hazardous drug; therefore, special handling (e.g., wearing impervious gloves) and disposal procedures are mandatory. Unused product, waste materials, and empty single-dose vials must be disposed of according to specialized environmental protection and pharmaceutical waste legislation, and must not be discarded into household garbage or sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ifex  found in:

A-Z Index: